Shionogi buys its way into China with planned C&O acquisition
This article was originally published in Scrip
Shionogi has announced plans to acquire the Singapore-listed Chinese pharmaceutical company C&O Pharmaceutical Technology (Holdings) for a total of around S$219 million ($182.5 million), in a move aimed at strengthening its presence in the increasingly critical Chinese pharma market.
You may also be interested in...
Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.
A busy stretch of deal-making across Asia all includes transactions involving Innovent, Alector, Ono, Numab, Alphamab, 3DMed, Healios, Athersys, Laekna, Novartis, Asahi Kasei, SBI Biotech, Glenmark, Hindustan Unilever, Hanlim, Alteogen, Ildong, Evotec, AJU Pharm, Ribomec, Tyligand, Context
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.